Table I.
Clinicopathological characteristics of patients with urothelial carcinoma (n=21).
| Characteristics | Paclitaxel and carboplatin chemotherapy (n=7) | Best supportive care (n=14) | P-value |
|---|---|---|---|
| Sex, male, n (%) | 4(57) | 13(93) | 0.054 |
| Median age (range), years | 62 (57-79) | 70 (58-85) | 0.108 |
| ECOG PS, n (%) | 0.546 | ||
| 0 | 3(43) | 3(21) | |
| 1 | 1(14) | 4(29) | |
| ≥2 | 3(43) | 7(50) | |
| Primary tumor site, n (%) | 0.874 | ||
| Bladder | 2(28) | 6(43) | |
| Upper urinary tract | 2(28) | 5(36) | |
| Bladder + upper urinary tract | 3(43) | 3(21) | |
| No. of chemotherapy before pembrolizumab | 0.931 | ||
| 1 | 4(57) | 9(64) | |
| 2 | 2(28) | 2(15) | |
| 3 | 1(14) | 3(21) | |
| Median time from first-line chemotherapy, months (95% CI) | 11.8 (4.7-31.1) | 15.8 (10.4-31.7) | 0.371 |
| Metastasis sites, n (%) | 0.129 | ||
| Lymph nodes only | 1(14) | 0 (0) | |
| Visceral disease | 6(86) | 14(100) |
ECOG PS, Eastern Cooperative Oncology Group Performance Status.